bonds (11-trans-LTC4 and 11-trans-LTD4, respectively) are also formed (1, 18) . The SRS activity of biological fluids is due predominantly to LTC4 and LTD4 (1, 2) .
Leukotriene generation by mastocytoma cells (11) , basophils (14, 15, 17) , macrophages (19) (20) (21) (22) , neutrophils (3, 4) , and h u m a n lung tissue (23) has been described; their formation by eosinophils, an important participant in immediate hypersensitivity reactions, however, has not been previously reported. We report here that horse eosinophils stimulated with the calcium ionophore A23187 generate LTB4, 5-(S), 12-
(R)-6-trans-LTB4, 5-(S), 12-(S)-6-trans-LTB4, LTC4, 11-trans-LTC4, and LTD4. M a t e r i a l s a n d M e t h o d s
Special Reagents. Leukotriene standards were obtained as follows. LTB4, 5-(S), 12-(R)-6-trans-LTB4 and 5-(S), 12-(S)-6-trans-LTB4 were isolated from A23187-stimulated human neutrophils (3, 4); LTC4, 11-trans-LTC4 and LTD4 were isolated from A23187-stimulated mouse mastocytoma cells (11, 15) ; synthetic LTC4 and LTD4 were kindly provided by Dr. J. Rokach, Merck Frosst Laboratories, Pointe-Claire/Dorval, Quebec (24) ; 3H-LTC4 from mouse peritoneal macrophages was the gift of Dr. C. A. Rouzer and Dr. W. A. Scott, The Rockefeller University, New York (21) .
The SRS antagonist FPL 55712 was kindly provided by P. Sheard, Fisons Limited, Pharmaceutical Division, Loughborough, England; 5,8,11,14-eicosatetraynoic acid (ETYA) was provided by Dr. W. E. Scott, Hoffmann-LaRoche, Inc., Nut|ey, N. J.; and the calcium ionophore A23187 was provided by Dr. J. Hosley, Lilly Research Laboratories, Indianapolis, Ind. Arachidonic acid, soybean lipoxygenase (type I), histamine diphosphate, indomethacin, fl-nicotinamide adenine dinucleotide, reduced form (fl-NADH), pyruvic acid (sodium salt, type II), lactate dehydrogenase (LDH), and polyvinylpyrrolidone (40,000 tool wt) were obtained from Sigma Chemical Co., St. Louis, Mo., and Amberlite XAD-7 was obtained from Mallinkrodt Chemical Works, St. Louis, Mo. [1-14C] arachidonic acid (>50 mCi/mmol) was obtained from Amersham Corp., Arlington Heights, Ill.
Isolation of Eosinophils.
Eosinophils were isolated from 10-40 liters of horse blood (kindly provided by the Florence Packing Co., Florence, Wash.), as previously described (25) . In brief, after 1 h of spontaneous sedimentation, the leukocyte-rich plasma and the upper quarter of the erythrocyte sediment were collected and centrifuged at 3,500 g for 15 min at 20°C. The eosinophils penetrated into the erythrocyte pellet during this centrifugation, whereas the remaining leukocytes formed a burly coat layer at the cell-plasma interface. The burly coat and platelet-containing plasma were removed by aspiration. Polyvinylpyrrolidone sedimentation followed by hypotonic lysis enabled a complete separation of the erythrocytes from the eosino~hils. The eosinophils were washed with 1% NaCI and resuspended at a concentration of 5 × 10 cells/ml in a standard salt solution, pH 7.2, consisting of 154 mM NaC1, 2.7 mM KC1, 4 mM Na2HPO4, 2.7 mM KH2PO4, 0.9 mM CaCI2, 0.8 mM MgSO4, and 6 mM glucose. The cell preparations consisted of98-100% eosinophils (<2% neutrophils), which were >98% viable as measured by trypan blue exclusion.
Isolation of Neutrophils. Neutrophils were isolated from horse blood as follows. 30 ml of a 1:3 blood: 0.9% NaC1 mixture was layered over 12 ml of Hypaque-Ficoll (specific gravity 1.0775) and the tubes centrifuged at 1,000 g for 40 min at 20°C. The upper layer, containing mononuclear cells, was removed by aspiration. The lower layer, containing polymorphonuclear leukocytes and erythrocytes, was mixed with 3% PVP (in 0.9% NaC1) and platelet-free horse plasma in a 3:2:1 mixture and allowed to sediment for 40 min at 4°C. The upper layer, containing neutrophils, was aspirated, and the cells were collected by centrifugation. Remaining erythrocytes were removed by hypotonic lysis, and the neutrophils were suspended in the standard salt solution. The neutrophil preparations were of >98% purity (1-2% eosinophils) and were >97% viable by trypan blue exclusion.
SRS and LDH Release. Duplicate samples of eosinophils or neutrophils were preincubated for 5 min at 37°C in standard salt solution, pH 7.2, in the presence and absence of arachidonic acid or inhibitors of arachidonic acid metabolism (see legends to figures and tables) in a water bath oscillating 80 times per min. The ionophore A23187 was then added to make a total volume of 1.0 ml. Unless otherwise indicated, incubations were for 15 min at 37°C, after which the suspensions were placed on ice until centrifugation at 400 g for 6 min at 4°C. The supernatants and pellets were stored at -70°C until hioassay of SRS activity or measurement of LDH activity.
SRS Bioassay. SRS activity was assayed on the atropinized, antihistamine-treated guinea pig ileum, as previously described (26) , using the model ABAC-100, Automatic Bio-Assay Controller, (ADAPS, Inc., Dedham, Mass.). 1 unit of SRS is defined as the concentration required to produce an ileal contraction equal in amplitude to that produced by 5.0 ng/ml histamine base. Peak contractions were measured 2 rain after addition of the samples. Varying concentrations of FPL 55712 were added to the 7.0-ml bioassay chamber to test for inhibition of SRS-induced contractions (27) . The reaction mixture was diluted at least 200-fold before application in the guinea pig ileal bioassay. None of the individual reaction mixture components (e.g., A23187, indomethacin, ETYA) caused ileal contraction or affected the contraction induced by synthetic LTC4 or LTD~ under the conditions used.
Measurement of LDH Release. LDH was measured using/~-NADH as substrate, as previously described (28) .
Purification ofEosinophil Leukotrienes. Column Chromatography. Eosinophils (3 × l0 s in 27 ml of the standard salt solution) were preincubated for 5 min at 37°C in a shaking water bath. The ionophore A23187 (10/~g/ml, final concentration) was then added to make a total reaction volume of 30 ml and a final cell concentration of 107 cells/ml. After 15 min, the cells were pelleted at 400 g for 10 rain at 4°C and discarded. The cell-free supernatant was adjusted to 80% ethanol (vol/vol). After storage for 16-20 h at 4°C, the ethanol suspension was centrifuged at 3,000 g for 10 min at 4°C, and the pellet was discarded. In some experiments, eosinophils were preincubated with radiolabeled arachidonic acid. [ 1-14C] arachidonic acid (150 #g; 24/~Ci) in a total volume of 0.9 ml was evaporated to dryness, redissolved in 0.1 ml ethanol, and added to the eosinophil preparation. After preincubation for 30 min at 37°C, A23187 was added, and the sample was treated as described above.
Reverse-Phase High-Pressure Liquid Chromatography (HPLC).
The dried eluant from the Amberlite XAD-7 column was resuspended in 300 #1 of methanol/water (65:35, vol/vol), containing 0.1% acetic acid (final pH, 3.9), centrifuged at 3,000 g for 15 min at 20°C, and the clear supernatant applied to a 3.9 X 300-mm #Bondapak Cls column (10 #m particle size) (Waters Assoc., Milford, Mass.). Elution was with the same solvent at a now rate of 1.0 ml/min and a pressure of 1,600 P.S.I., using either a Waters model ALC 244 or model 334 MP (Beckman Instruments, Inc., Berkeley, Calif.) HPLC apparatus. The optical density of the column eluant was continuously recorded at 280 nm, and sequential 1-ml fractions were collected for assay of SRS activity. After 40 rain of isocratic elution, a linear methanol gradient from 65 to 100% was applied to the column to remove all absorbed lipids. Biologically active fractions were evaporated to dryness under nitrogen and resuspended in a small volume of the methanol/ water/acetic acid solvent. To obtain chromatographically pure compounds, each sample was rechromatographed at least twice, either as described above or on a 4.6 × 250-ram Ultrasphere ODS Cls column (5 #m particle size; Altex Scientific Co., Berkeley, Calif.) with a mobile phase of methanol/water (72:28, vol/vol) with 0.1% acetic acid, pH 3.9, and a flow rate of 1 ml/min.
For identification, the samples underwent additional rechromatography on each of the two columns described above and on a 4.6 × 250-ram Nucleosil Cls, 5/~m particle size column (Machery-Nagei, Diiren, West Germany) with a methanol/water (65:35, vol/voi) 0.01% acetic acid, pH 5.7, mobile phase and a flow rate of 1.5 ml/min, and their retention times were compared to those of appropriate standards.
Ultraviolet Spectrometry. The UV spectra of the rechromatographed compounds were determined using a Cary 219 spectrophotometer (Cary Instruments, Monrovia, Calif.). In some experiments the measurements were made before and after incubation of the compound in the standard salt solution with soybean lipoxygenase (10 #g/ml) for 30 rain at 20°12 (11).
Gas Chromatography-Mass Spectrometry. Compounds that co-eluted on HPLC with the LTB4, 5-(S), 12-(R)-6-trans-LTB4 and 5-(S), 12-(S)-6-trans-LTB4 standards were derivatized by methylation with diazomethane and trimethylsilylation with bis(trimethyl)trifluoroacetomide. Derivatives were analyzed by gas chromatography-mass spectrometry using a Finnigan 3200 quadrupole mass spectrometer (Finnigan Corp., Sunnyvale, Calif.) under electron impact (70 eV) conditions. Gas chromatographic separation was performed using 3% OV-101 on Supelcoport (140-160 mesh) in a glass column 0.2 × 150-cm and temperature programming 240 ° to 280 ° at 8°/min. Equivalent chain length was determined by coinjecting reference fatty acid methyl esters, as previously described (29) .
Statistical Analysis. The data are reported as the mean ± SE of the combined experiments.
Differences were analyzed for significance using Student's two-tailed t test for independent means (not significant, P > 0.05).
Results
Incubation of eosinophils with the calcium ionophore A23187 results in the release into the extracellular medium of an agent or agents that induces contraction of the guinea pig ileum. The characteristics of that contraction are those of SRS--a slow, sustained contraction in the presence of atropine and an antihistamine. Further, contraction was inhibited by the SRS antagonist FPL 55712. The concentration necessary to produce a 50% reduction of the guinea pig ileal contractile response (ICs0) was ~ 11 ng/ml (Table I) , which is consistent with the concentrations of FPL 55712 reported to block 50% of the activity of the SRS obtained from guinea pig lung (27) , rat basophilic leukemia cells (30) , and rat peritoneal mast cells (31) . Other smooth muscle stimulants, such as prostaglandins, serotonin, and bradykinin, are considerably less sensitive to FPL 55712: the ICs0 for these stimulants is 1,000 times greater than that for SRS (27) . This suggests that most if not all of the smooth muscle contracting activity released from eosinophils by A23187 is due to SRS.
SRS production by eosinophils (5 × 106 cells/ml) increased with A23187 concentration to reach a maximum at 10 #g/ml (1.9 × 10 -5 M) ( Fig. 1) with LDH release <5% at these concentrations. When the ionophore concentration was raised to 20 #g/ ml (3.8 × 10 -5 M), SRS formation decreased and LDH release increased, suggesting cytotoxic injury to the cells. Unless otherwise indicated, the ionophore concentration used was 10 #g/ml. SRS release was evident 1 min after the addition of ionophore and increased with time to reach a maximum at 15-30 rain (data not shown). Incubation for 15 min at 37°C was routinely used.
TAnLE I

Inhibition of Eosinophil SRS Activity by FPL 55712
FPL 55712
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120.
•'/ Because SRS is also a product ofneutrophil stimulation by A23187, the contribution of the 1-2% neutrophil contamination of the eosinophil preparations was assessed. Fig. 2 compares SRS release by horse neutrophils (98% pure) to that of the eosinophil preparation over a range of cell concentrations from 2.5 × 106 to 25 × 106 per ml. SRS generation by the eosinophil preparations was four to five times that of the neutrophil preparations at all cell concentrations, suggesting that neutrophils do not contribute significantly to the SRS generated by the eosinophil preparations.
The effect of arachidonic acid or inhibitors of araehidonic acid metabolism on SRS production by eosinophils is shown in Table II . Arachidonic acid at 3.0 #g per ml increased A23187-induced SRS release 31.5%, whereas lower (0.3 #g/ml) or higher (30.0 #g/ml) concentrations had no significant effect. ETYA, an inhibitor of both the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism (32), significantly inhibited A23187-induced eosinophil SRS production at concentrations of 10 and 100 #g per ml, whereas indomethacin, a selective inhibitor of the cyclooxygenase pathway (32), increased SRS production at a concentration of 1.0 #g per ml. In each of eight experiments, 3 × 10 s eosinophils were suspended in 30 ml of the standard salt solution and stimulated with 10 #g/ml A23187. After ethanol extraction and Amberlite XAD-7 chromatography, the components of the preparation were separated by HPLC. Fig. 3 demonstrates a typical elution pattern of the 280 nm absorbing material. Five 280-nm absorbing peaks with elution times between 11 and 26 min (designated I to V) were found to have SRS activity. All compounds were radiolabeled when stimulation of eosinophils by A23187 was performed in the presence of [t4C]arachidonic acid. The SRS ileal contracting activity of compounds I, II, and III were not blocked by FPL 55712, whereas 11 ng/ml FPL 55712 produced a 50% reduction of contractions induced by compounds IV and V. Other characteristics of compounds I to V are indicated below.
Compound I. Compound I, which accounted for 1.8% of the total eosinophil SRS activity, had a retention time of 11.9 min under our standard HPLC conditions (Table III) . Its UV spectrum was characterized by a peak at 269 nm and two smaller peaks at 259 and 280 3= 1 nm (Fig. 4A) Eosinophils (5 × 10 e) in 1.0 ml of the standard salt solution were preincubated with the supplements at the concentrations indicated for 5 min at 370C, after which 10 #g/ml of A23187 was added. SRS release was determined after an additional 15 rain of incubation. Probability values for the difference from eosinophils plus A23187 alone (none) are shown where significant, The results are the mean + SE of five experiments. The retention times of the rechromatographed eosinophil compounds were compared in three different HPLC systems: Column A: 3.9 × 300-ram, ~Bondapak Cxa (10 btm particles); solvent, methanol/water (65:35, vol/vol) with 0.1% acetic acid, pH 3.9; flow rate, 1.0 ml/min. Column B: 4.6 X 250-mm Ultrasphere ODS C1s (5/zm particles); solvent, methanol/water (72:28, vol/vol) with 0.1% acetic acid, pH 3.9; flow rate, 1.0 ml/min. Column C: 4.6 × 250-mm, Nucleosil CIS (5 ~m particles); solvent, methanol/water (65:35, vol/vol) with 0.01% acetic acid, pH 5.7; flow rate, 1.5 ml/min. The results are the mean of eight experiments.
and had a retention time of 13.4 min under our standard HPLC conditions (Table  III) . It had the same UV spectrum (Fig. 4A ) and identical gas chromatography-mass spectral characteristics as compound I. Compound II co-eluted on each HPLC column with 5-(S), 12-(S)-6-trans-LTB4. Compound III. Compound III accounted for 3.4% of the total eosinophil SRS activity and had a retention time of 14.8 rain on our standard HPLC conditions (Table III) . Its UV spectrum was characterized by a peak at 270 nm, with two smaller peaks at 260 and 281 -+ 1 nm (Fig. 4B) . Gas chromatography of the derivative indicated an equivalent carbon number of 23.5, and its mass spectral characteristics were identical to that of authentic LTB4. Compound III co-eluted with LTB4 under each of three HPLC conditions. Compound IV. Compound IV, the predominant eosinophil SRS, as measured by bioactivity (66% of the total SRS), had a retention time of 16.4 min under our standard HPLC conditions (Table III, Fig. 5 ). Its UV absorption spectrum had a peak at 280 nm, with shoulders at 270 and 292 + 1 nm (Fig. 4C) , which is consistent with a sulfur substituent a to a conjugated triene (33) . The absorption spectrum shifted to a peak at 308 nm on incubation of compound IV with soybean lipoxygenase; this enzyme also decreased the ileal contracting activity of compound IV by >90%. Compound IV co-eluted on HPLC with LTC4 obtained from mouse mastocytoma cells and peritoneal macrophages and also with synthetic LTC4 (Fig. 5) . A small amount of 11-trans-LTC4 was found eluting closely after the eosinophil LTC4 on rechromatography.
Compound V. Compound V accounted for 26.8% of the eosinophil SRS activity and had a retention time of 24.9 min under our standard HPLC conditions (Table  III) . It had the same absorption spectrum (Fig. 4 C) and response to lipoxygenase as did compound IV. Compound V co-eluted with synthetic and mouse mastocytoma LTD4 on each of the HPLC columns. LTC4; and compound V is LTD4. The final yield of each compound from 3 × l0 s eosinophils was 0.7 pg for compound I, 0.8/~g for compound II, 1.1/~g for compound III, 3.6 pg for compound IV, and 0.3 #g for compound V, as determined from their UV spectra, using the reported extinction coefficients for each of the identified leukotrienes (3, 4, 13, 23) . This is an underestimate of the total production because it does not take into account the recovery during the isolation procedures. Beginning with 25,400 SRS units per 3 × 10 s eosinophils in the initial supernatant, we recovered 10,500 SRS units in the final HPLC eluates, a recovery of 41%. Horse neutrophils (3 × 10 a) treated in an identical fashion yielded 0.8 pg of LTC4, which corresponds closely to the lower SRS activity produced by neutrophils compared to eosinophils shown in Fig. 2 . Discussion Our data indicate that horse eosinophils can metabolize arachidonic acid by the lipoxygenase pathway to form leukotrienes with potent SRS activity. Eosinophils highly purified to >98% were found to generate FPL 55712-inhibitable SRS activity without release of appreciable LDH when stimulated with 10 ~g/ml of the calcium ionophore A23187.
Horse eosinophils generated up to five times the amount of SRS produced by similarly treated horse neutrophils when compared on a per cell basis. Thus, of the ~138 units of SRS bioactivity generated by 25.0 × 10 e eosinophils, <1 SRS unit could be attributed to neutrophil contamination (2% neutrophils each with % the activity on a per cell basis). Leukocyte preparations consisting predominantly of neutrophils when incubated with 1-10/tg/ml ionophore A23187 generate SRS (34) and leukotrienes (3) (4) (5) . Because these preparations contained a variable proportion of eosinophils, eosinophil contribution to the leukotriene generation may be significant.
The inhibition of eosinophil SRS release by ETYA and augmentation of its release by araehidonic acid and indomethacin are consistent with other reports (I 1, 35) that SRS is a lipoxygenase product of arachidonic acid. This was confirmed by separation and identification of specific leukotrienes. Leukotrienes were isolated in pure form by Amberlite XAD-7 and repeated HPLC chromatography. Individual compounds were identified by comparison of their retention times on HPLC under three different conditions to authentic standards, by their characteristic ultraviolet spectra and spectral shift after treatment with soybean lipoxygenase, by their incorporation of [a4C]arachidonic acid, and by gas chromatography and mass spectrometry as indicated in the text. The eosinophil products by these criteria were 5-(53, 12-(R)-6-trans-LTB,.
5-(53, 12-(S)-6-trans-LTB4, LTB4, LTC4, 11-trans-LTC,, and LTD4. A23187-stimulated human eosinophils obtained from patients with the hypereosinophilic syndrome produced the same leukotrienes (5-(S), 12-(R)-6-trans-LTB,, 5-(53, 12-(S)-6-trans-LTB,, LTB4, LTC4, and LTD4) as did horse eosinophils. 2 Greater than 92% of the eosinophil SRS bioactivity was contributed by LTC4 and LTD4. The myotrophic properties of LTB4 and its isomers on lung parenchymal strips (7) and guinea pig ileum (36) have only recently been recognized. This property, which was also observed during the course of these investigations, may be due to the release of thromboxanes and prostaglandins induced by LTB4 in the bioassay system (7, 36) . Thus, our findings suggest that eosinophils, when appropriately stimulated, are a potent source of leukotrienes. Eosinophilia is commonly seen in patients with bronchial asthma (37) , where a rise in eosinophil counts has been associated with a deterioration of pulmonary function and a concomitant increase in clinical symptoms (38) . Eosinophils may play a causal role in asthma by their capacity to generate leukotrienes with potent SRS activity. Eosinophil production of leukotrienes, which increase vascular permeability and have potent chemotactic and smooth muscle contracting activity, may also be of great significance in the host defense against certain neoplasms and helminths, where eosinophils are found in greatly increased numbers.
Summary
Horse eosinophils purified to>98% generated slow reacting substance (SRS) when incubated with the calcium ionophore A23187. On a per cell basis, eosinophils generated four to five times the SRS produced by similarly treated horse neutrophils. Eosinophil SRS production was inhibited by 5,8,11,14-eicosatetraynoic acid and augmented by indomethacin and arachidonic acid, suggesting that it was a product(s) of the lipoxygenase pathway of araehidonic acid metabolism. Compounds with SRS activity were purified by high-pressure liquid chromatography (HPLC) and identified by ultraviolet spectra, spectral shift on treatment with lipoxygenase, incorporation of [14C]arachidonic acid, gas chromatography-mass spectrometry, and comparison of retention times on HPLC to authentic standards. The eosinophil products character- 
